checkAd
    Startseite > Aktien > Repare Therapeutics > Nachrichten
    Repare Therapeutics Aktie
    3,4800
     
    USD
    +3,88 %
    +0,1300 USD
    Letzter Kurs 01.06.24 Nasdaq
    3,4800
     
    USD
    800 STK
    Geldkurs 31.05.24
    3,5100
     
    USD
    100 STK
    Briefkurs 31.05.24
    ISIN: US7602731025 · WKN: A2P7AV · SYM: RPTX · Kanada

    Neueste Nachrichten

    Repare Therapeutics to Present Initial Phase 1 MINOTAUR Data at ESMO GI Congress 2024
    29.05.24 · Business Wire (engl.) · Repare Therapeutics
    Repare Therapeutics Provides Business and Clinical Update and Reports First Quarter 2024 Financial Results
    07.05.24 · Business Wire (engl.) · Repare Therapeutics
    Debiopharm & Repare Therapeutics Announce First Patient Dosed in Phase 1/1b Mythic Trial Evaluating the Synthetic Lethal Combination of WEE1 AND PKMYT1 Inhibition
    30.04.24 · Business Wire (engl.) · Repare Therapeutics
    Repare Therapeutics & Debiopharm Announce First Patient Dosed in Phase 1/1b MYTHIC Trial Evaluating the Synthetic Lethal Combination of PKMYT1 and WEE1 Inhibition
    30.04.24 · Business Wire (engl.) · Repare Therapeutics
    Repare Therapeutics Appoints Steven H. Stein, M.D. to its Board of Directors
    26.04.24 · Business Wire (engl.) · Repare Therapeutics
    Repare Therapeutics Inc. (RPTX) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Seek Compensation for Alleged Wrongdoings
    21.03.24 · Business Wire (engl.) · Repare Therapeutics
    Repare Therapeutics Inc. (RPTX) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Seek Compensation for Alleged Wrongdoings
    15.03.24 · Business Wire (engl.) · Repare Therapeutics
    Repare Therapeutics to Participate in Two Upcoming Investor Conferences
    29.02.24 · Business Wire (engl.) · Repare Therapeutics
    Repare Therapeutics Provides Business Update and Reports Fourth Quarter and Full Year 2023 Financial Results
    28.02.24 · Business Wire (engl.) · Repare Therapeutics
    Kirby McInerney LLP Announces Investigation of Shareholder Claims Against Repare Therapeutics Inc. (RPTX)
    17.02.24 · Business Wire (engl.) · Repare Therapeutics
    Repare Therapeutics Doses First Patient in Phase 1 Clinical Trial of RP-1664
    15.02.24 · Business Wire (engl.) · Repare Therapeutics
    Repare Therapeutics to Regain Global Rights to Camonsertib
    12.02.24 · Business Wire (engl.) · Repare Therapeutics